Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Circulating tumor cell (CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment for metastatic castration-resistant prostate cancer. We assessed the prognostic value of CTCs for overall survival (OS) and disease response in S0421, a phase III trial o...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Goldkorn, Amir, Ely, Benjamin, Quinn, David I., Tangen, Catherine M., Fink, Louis M., Xu, Tong, Twardowski, Przemyslaw, Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk, J. Paul, Datar, Ram H., Garzotto, Mark, Mack, Philip C., Lara, Primo, Higano, Celestia S., Hussain, Maha, Thompson, Ian Murchie, Cote, Richard J., Vogelzang, Nicholas J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2014
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3970171/
https://ncbi.nlm.nih.gov/pubmed/24616308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.7417
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky